Maitake is a food before it's a supplement, and its safety record reflects that. Two clinical trials covering 52 patients reported no dose-limiting toxicity and no serious adverse events. The cautions live somewhere else — in two drug interactions, and in one finding almost nobody quotes: in the only dose-escalation trial ever run on maitake, higher doses didn't produce more immune activity. They produced different immune activity, and some of it moved the wrong way.
Direct side effects are mild and mostly digestive — nausea, loose stools, and in one 12-week trial a rise in eosinophils in 4 of 18 patients. The meaningful risks are interactions. A published case report links maitake extract to a rise in INR in someone taking warfarin, and a 2001 clinical note describes two people with type 2 diabetes whose glibenclamide had to be cut or withdrawn after they added 500 mg of maitake a day. Skip it before surgery, and don't combine it with anticoagulants or diabetes medication unless someone is monitoring your numbers.
Most maitake safety writing says "generally well tolerated" and stops. That's accurate and nearly useless, because it skips the two situations where maitake has actually changed something measurable in a real patient — and both of those involve a prescription drug, not the mushroom on its own.
What Does the Human Safety Data Actually Show?
Two trials carry most of the weight, and between them they cover 52 people. The larger is a phase I/II dose-escalation study in 34 postmenopausal breast cancer patients who were disease-free after treatment (Deng et al., J Cancer Res Clin Oncol, 2009). Five cohorts took a maitake liquid extract at 0.1, 0.5, 1.5, 3 or 5 mg/kg twice daily for three weeks. Safety and tolerability were the primary endpoints. No dose-limiting toxicity was reached, even at the top dose.
The second is a phase II study in 18 patients with myelodysplastic syndromes, dosed at 3 mg/kg twice daily for 12 weeks (Wesa et al., Cancer Immunol Immunother, 2015). No serious adverse events, and nothing above grade 1 on the CTCAE scale.
Both trials ran in patient populations rather than healthy volunteers, which cuts both ways. These people were monitored closely, so small signals got caught. They were also not typical supplement buyers.
Why More Maitake Isn't More Immune Support
This is the finding worth the price of the article. In the 2009 dose-escalation trial, the association between maitake dose and immunologic function was strongly significant (p < 0.0005) — but it wasn't a ramp. Increasing doses raised some immune parameters and depressed others, and the dose-response curves for many endpoints were non-monotonic, with intermediate doses producing either enhancement or suppression depending on which marker you looked at.
Read that against how maitake is sold. Every label implies a straight line: more beta-glucan, more immune support. The one human study designed to test the shape of that line found something else. Taking a bigger dose isn't just wasteful here — it might push the exact parameter you care about in the wrong direction.
Two honest caveats. This was a three-week study in 34 people, and the endpoints were immune markers measured in the lab, not infections avoided or outcomes changed. Nobody has run the follow-up. But it's the only map of maitake's dose-response we have, and it isn't the shape the marketing assumes.
What Are the Common Side Effects at Ordinary Doses?
Digestive, mild, and early. In the 12-week myelodysplastic syndrome trial, two of 18 patients reported diarrhoea and one reported nausea, all grade 1. One patient withdrew because the diarrhoea persisted. That's roughly the pattern you'd expect from any concentrated fungal polysaccharide: the gut notices first.
These effects tend to be dose-related and tend to fade. Taking maitake with food and splitting the daily amount into two servings resolves most of it, which is the same advice our maitake dosage guide gives for tolerability generally.
Eosinophilia: The Lab Finding Worth Knowing About
Four of the 18 patients in the 2015 trial developed eosinophilia, with a mean increase of 1.37 K/mcL (p = 0.011). It was asymptomatic in every case and graded 1. Both patients who reported diarrhoea also had it, which hints at a low-grade allergic-type response rather than anything sinister.
Two smaller numbers from the same trial deserve a mention, because they run against expectation. Haemoglobin fell slightly but significantly, from 11.5 to 11.0 g/dL (p = 0.003), though no patient became anaemic. And the neutrophil count dropped by 0.3 K/mcL (p = 0.044) — the authors called it not clinically meaningful, and it probably isn't. It's still the opposite direction from what a mushroom marketed for white-cell support is supposed to do.
Practical takeaway: if you're on maitake long-term and get routine bloodwork, mention it to whoever reads the results. An unexplained eosinophil rise has a boring explanation sitting in your supplement drawer.
Does Maitake Interact With Warfarin?
One published case report says yes. Hanselin and colleagues described INR elevation in a patient taking maitake extract alongside warfarin (Ann Pharmacother, 2010;44(1):223-224), and proposed that maitake displaced warfarin from protein binding, leaving more free drug in circulation. A single case can't establish causation, and the authors didn't claim it did.
But the direction of the risk matters more than its certainty. An unexpected INR rise on warfarin means bleeding, not a mild inconvenience. If you take warfarin and want to try maitake, that's a conversation with your prescriber and a check of your INR a week or two later — not a decision to make from a product page.
The same logic covers surgery. Stop maitake one to two weeks before any planned procedure, the standard precaution for supplements with any bleeding signal. Our Reishi side effects guide covers the same ground for a mushroom with a stronger antiplatelet story.
The Diabetes Interaction Is the Best-Documented One
Here the evidence is thin in volume but unusually concrete. A 2001 clinical note in Diabetic Medicine reported two patients with type 2 diabetes who added 500 mg maitake caplets daily while taking glibenclamide (Konno et al., Diabet Med, 2001;18(12):1010). Blood glucose fell far enough that the glibenclamide dose was reduced in one patient and withdrawn in the other, with glucose staying in range afterwards.
Think about what that means. Two prescriptions were changed because of a mushroom. That's a stronger practical signal than a dozen "may lower blood sugar" disclaimers, and it's the clearest documented effect in the whole maitake literature.
Konno also reported a small open pilot of maitake SX-fraction in adults with type 2 diabetes the same year (Altern Complement Ther, 2001), with fasting glucose falling over two to four weeks. No control group, tiny sample — suggestive, not proof. The supporting rodent work is more consistent than the human work, which is the usual shape of things. Our article on maitake and blood sugar goes through that evidence in detail.
If you take insulin or a sulfonylurea, additive hypoglycaemia is the risk, and it's real enough to test for. Check your glucose more often for the first two weeks after starting.
Interaction Summary
| Drug or class | Concern | Evidence level | What to do |
|---|---|---|---|
| Warfarin | INR elevation, bleeding risk | One case report (2010) | Check INR 1–2 weeks after any change |
| Insulin, sulfonylureas | Additive hypoglycaemia | Clinical note, 2 patients; pilot study | Monitor glucose; expect possible dose change |
| Antiplatelets, aspirin | Theoretical bleeding risk | Extrapolated from the warfarin case | Discuss before combining |
| Immunosuppressants | Possible opposing action | Mechanistic only, no human data | Avoid unless supervised |
| Antihypertensives | Possible additive lowering | Rodent data only | Monitor if already well controlled |
What About Immunosuppressants and Autoimmune Disease?
No human data exists in either direction, so what follows is reasoning rather than evidence. Maitake's beta-glucans engage innate immune receptors, which is the entire point of taking it. Someone on tacrolimus or ciclosporin is trying to achieve the opposite. Those two goals don't sit together, and nobody has studied what happens when they collide.
The same caution applies loosely to active autoimmune disease. It's worth saying plainly that the 2009 trial found maitake could depress immune parameters as well as raise them, so even the direction of the interaction isn't a given. Uncertainty is the honest answer here, and uncertainty plus an immune-modifying drug is a reason to ask a specialist rather than guess.
Who Should Avoid Maitake?
- Anyone taking warfarin or another anticoagulant, unless INR is being monitored
- Anyone on insulin or a sulfonylurea without glucose monitoring in place
- Anyone within one to two weeks of planned surgery
- People taking immunosuppressant drugs after a transplant
- Pregnant or breastfeeding women — no safety data at supplement doses, which is a gap, not a reassurance
- Children, for the same reason
- Anyone with a known mushroom allergy
Everyone else, at studied doses, is in reasonably well-mapped territory. The comparison articles for lion's mane and cordyceps reach similar conclusions with different specifics.
Is Eating Maitake as Food Any Different?
Yes, and the distinction gets blurred constantly. Maitake has been eaten in Japan for centuries and is sold as a culinary mushroom in ordinary quantities. Nothing in this article argues against cooking with it. The trials above used concentrated liquid extracts dosed by body weight — a different exposure entirely, and the reason a food-safety record can't simply be transferred to a supplement bottle.
One genuine maitake risk sits outside both categories. Occupational hypersensitivity pneumonitis from inhaled maitake spores is documented: a 49-year-old woman developed it three months into work on a maitake farm, relapsed five months after oral steroids, and was eventually controlled on an inhaled corticosteroid (Intern Med, 2004;43(8):737). That's a growing-shed exposure, not a kitchen or a capsule. Worth knowing about, wrong to cite as a supplement risk — and it gets cited that way often.
How Do You Lower Your Risk?
- Stay inside studied doses. The trials used 3 mg/kg twice daily at the high end, and the dose-escalation data gives no reason to go past that.
- Start at the bottom of the range for a week. Most digestive effects show up early and resolve.
- Take it with food, split across two servings.
- If you take warfarin or a diabetes drug, monitor the relevant number for the first fortnight after any change — starting, stopping, or switching brands.
- Check what's actually in the bottle. A product that lists "polysaccharides" without a beta-glucan figure hasn't told you the dose you're taking, as our label-reading guide explains.
Frequently Asked Questions
Does maitake have serious side effects?
Not at studied doses. Across 52 patients in two clinical trials there were no serious adverse events and no dose-limiting toxicity. Reported effects were grade 1: nausea, diarrhoea, and asymptomatic eosinophilia in 4 of 18 patients in the longer trial.
Can you take maitake with blood thinners?
Not without supervision. A 2010 case report describes INR elevation in a patient combining maitake extract with warfarin, with protein-binding displacement proposed as the mechanism. One case isn't proof, but the consequence of being wrong is bleeding, so treat it as a real caution.
Does maitake lower blood sugar too much?
On its own, unlikely. Combined with medication, it can. Two patients described in Diabetic Medicine in 2001 needed their glibenclamide reduced or withdrawn after adding 500 mg of maitake daily. Monitor closely if you're on insulin or a sulfonylurea.
Should you cycle maitake or take breaks?
No cycling protocol has been tested, and no tolerance has been described. The longest trial dosed continuously for 12 weeks without a break. Cycling advice for maitake is generic supplement folklore rather than anything drawn from its own literature.
Is more maitake better for immunity?
The only dose-escalation trial says no. Immune parameters responded to dose non-monotonically (p < 0.0005), with some markers rising and others falling as the dose went up. Higher isn't reliably stronger, and it may not even be the same direction.
A Note on What We Sell
We don't stock maitake. That's worth saying in an article like this one, because safety pages usually end with a product you're supposed to trust the author about. If you're buying maitake elsewhere, the label questions in our supplement label guide apply unchanged: species named, fruiting body or mycelium stated, beta-glucan quantified. Our immunity collection covers the species we do carry, with the same evidence standard applied.
Related Articles
- Maitake Mushroom Dosage Guide
- Maitake and Blood Sugar
- Maitake D-Fraction and Immune Support
- Best Time to Take Maitake
- Maitake vs Reishi
- Shiitake vs Maitake
Sources
- Deng G, Lin H, Seidman A, et al. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res Clin Oncol. 2009;135(9):1215-1221. PubMed 19253021
- Wesa KM, Cunningham-Rundles S, Klimek VM, et al. Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study. Cancer Immunol Immunother. 2015;64(2):237-247. PMC4317517
- Hanselin MR, Vande Griend JP, Linnebur SA. INR elevation with maitake extract in combination with warfarin. Ann Pharmacother. 2010;44(1):223-224. PubMed 20040699
- Konno S, Tortorelis DG, Fullerton SA, et al. A possible hypoglycaemic effect of maitake mushroom on Type 2 diabetic patients. Diabet Med. 2001;18(12):1010. PubMed 11903406
- Tanaka H, Tsunematsu K, Nakamura N, et al. Successful treatment of hypersensitivity pneumonitis caused by Grifola frondosa (Maitake) mushroom using a HFA-BDP extra-fine aerosol. Intern Med. 2004;43(8):737-740. PubMed 15468977
- Memorial Sloan Kettering Cancer Center. Maitake — Integrative Medicine herb monograph. mskcc.org